ABSTRACT
Objective To investigate the relationship between the expressions of osteopontin (OPN), matrix metalloproteinase 2 (MMP-2) and vascular endothelial growth factor (VEGF) in gastric cancer and the poor prognosis of gastric cancer patients. Methods A total of 35 patients with gastric cancer after radical gastrectomy from January 2014 to March 2015 in Dalian Third People ' s Hospital were retrospectively analyzed. The expressions of OPN, MMP-2 and VEGF in gastric cancer tissues and adjacent normal tissues were detected by immunohistochemical SP staining. The relationship between the expressions of OPN, MMP-2 and VEGF and the poor prognosis of gastric cancer patients was analyzed. Results The positive expression rates of OPN, MMP-2 and VEGF in postoperative pathological tissues of gastric cancer were 80.0％ (28/35), 77.1％(27/31) and 88.6％(31/35), respectively. OPN expression was associated with vascular invasion, lymph node metastasis, degree of differentiation, degree of invasion, and Lauren classification (all P< 0.05). MMP-2 expression was associated with vascular invasion, lymph node metastasis, and degree of invasion (all P<0.05). VEGF expression was associated with vascular invasion, lymph node metastasis, degree of invasion, and Lauren classification (all P< 0.05). OPN, VEGF and MMP-2 had synergistic effects in the invasion and metastasis of gastric cancer, and the expressions of them were positively correlated (all P< 0.05). The sensitivity of combined detection of OPN, VEGF and MMP-2 (87.5％) was higher than the sensitivity of individual detection (68.8％, 62.5％ and 56.3％) (P< 0.05). Conclusions OPN, MMP-2 and VEGF expressions are closely related to the poor prognosis of gastric cancer patients, and have synergistic effects in the invasion and metastasis of gastric cancer. The combined detection of OPN, MMP-2 and VEGF may have a more accurate prediction of the prognosis of gastric cancer.
ABSTRACT
Objective To evaluate the efficacy and safety of xiaoaiping combined with XELOX (oxaliplatin and capecitabine) regimen chemotherapy in the treatment of advanced metastatic gastric adenocarcinoma. Methods This was a randomized, open label and parallel controlled study. Sixty-two advanced metastatic gastric adenocarcinoma patients with KPS score ≥60 scores and expected survival time≥3 months were enrolled. The patients were divided into experiment group and control group with 31 cases each. The patients in experiment group received xiaoaiping combined with XELOX regimen chemotherapy, and the patients in control group received XELOX regimen chemotherapy, 21 d was a cycle. The efficacy and adverse events were observed and compared. Results Twenty-nine patients in experiment group and 27 in control group completed treatment. The response rate and disease control rate in experiment group were significantly higher than those in control group: 48.3% (14/29) vs. 33.3% (9/27) and 89.7% (26/29) vs. 74.1% (20/27), and there were statistical differences (P＜0.05). The median progression-free survival time in experiment group was significantly longer than that in control group: 6.3 months vs. 5.1 months, and there was statistical difference (P=0.041). The median overall survival time in experiment group was significantly longer than that in control group: 9.6 months vs. 7.4 months, and there was statistical difference (P = 0.029). The most common adverse events in 2 groups were nausea vomiting, hand-foot syndrome, neutropenia thrombocytopenia, leucocytopenia, hepatic functional lesion, neurotoxicity, oral mucositis and diarrhea. The incidences of nausea vomiting, neutropenia thrombocytopenia, leucocytopenia and diarrhea in experiment group were significantly lower than those in control group, and there were statistical differences (P＜0.05). Conclusions Xiaoaiping combined with XELOX regimen chemotherapy in the treatment of advanced metastatic gastric adenocarcinoma can obviously improve the short-term curative effect, prolong the patients′survival time, reduce the adverse reaction of chemotherapy, and bring clinical benefits to the patients.